EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.
  • Home
  • Technology
    全部 Engineering expression platform Antibody Humanization Antibody Affinity Maturation Phage Display Antibody Library Bispecific Antibody CAR-T
  • About Us
    全部 Corporate Honors Introduction Team History
  • Product
    全部 Drug Discovery Scientific research products Project cooperation Alpaca natural nanoantibody phage display library Alpaca antigen injection and alpaca blood collection Antibody customization Antibody humanization maturation of antibody affinity Human natural antibody phage display library YK012 Diagnostic and therapeutic neutralizing antibodies against COVID-19
  • News
  • Job
  • Contact

  1. Home
  2. News

Series A financing of Detong Capital and Qianhai Master Fund

2020-12-10 10:02:35 admin 4

图片关键词

图片关键词

In December 2020, Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. completed a round A financing of tens of millions of yuan, which was jointly led by Detong Capital and Qianhai Master Fund.

  • Previous : The company won the second prize in the first "Future Star" biomedical innovation transformation project competition in 2021
  • Next : National high-tech enterprises
  • News

为你推荐

  • Nature Major findings: lower affinity agonist antibody is more effective
  • Phase I clinical trial project of YK012 for injection was officially launched
  • The 2022 year-end summary meeting ended successfully
  • The leaders went to the Sino-Science Life Science Industrial Park for investigation
  • Fight against COVID-19 - EXCYTE is in action

版权所有 2017-2026 京ICP备17063430号

5 Kaituo Road, Haidian District, Beijing (Zhongguancun Bio-medicine Park) Room B306-308

133-0121-5426

Powered by  MetInfo  7.5.0